Trades and observations from a British contrarian stock investor

This blog is not intended to give financial advice. Before investing, do your own research and consult your financial adviser if appropriate. The accuracy of any information included is not guaranteed and may be subject to conjecture or interpretation by Contrarian Investor. Therefore visitors should validate all facts using alternative sources where possible.

Monday, February 21, 2011

Sareum Holdings - a pharmaceutical cancer development company that's more of an acorn than an oak!

On average it costs more than $1 billion and takes more than seven years to undertake clinical trials and win regulatory approval before a new drug can be marketed. Only one out of every six (16%) drugs developed ever makes it to marketing approval. With this in mind and with poor productivity from their own internal research and development activities, major pharmaceutical companies are increasingly looking at smaller external development entities to license products from.

AIM listed, Sareum Holdings (SAR) is focused on finding new development compounds to treat cancer for future potential development with third party drug companies. 


Sareum was founded in August 2003 by Dr Tim Mitchell, Dr David Williams and Dr John Reader as a spin out from Millennium Pharmaceuticals' Structure-Based Discovery Department. Following an initial private investment, the company was successfully admitted to the Alternative Investment Market (AIM) of the London Stock Exchange in October 2004.

In 2008, the company restructured its business to concentrate solely on its internal cancer drug discovery programmes. It is based in Cambridge, U.K..

Development focus
Sareum is focusing research on drugs that target the biochemical processes which control cell growth and division in cancerous tumours including


  • Checkpoint Kinase 1 (Chk1)
  • Aurora Kinase (Aurora)
  • FMS-like Tyrosine
  • Kinase 3 (FLT3)
  • Anaplastic Lymphoma Kinase (ALK)
  • Polo-Like Kinase (PLK)
  • B-raf
Once a solid cancer tumour reaches a certain size, it needs to be connected to the body's blood and lymph systems to receive nutrients and remove waste. Vascular Endothelial Growth Factor Receptor 3 Kinase, (VEGFR-3, sometimes referred to as Fms-like Tyrosine Kinase 4, FLT4) is importantly involved in the generation of new blood and lymph vessels to a tumour. VEGFR-3 is also involved in the control of metastasis whereby the cancer spreads around the body, which is the main cause of death in cancer patients. Many cancer cells are highly dependent on fatty acid levels of which Fatty Acid Synthase (FASN) is a key regulator.


Sareum’s lead development product is SAR-020106 that has been developed as a CHK1 inhibitor in conjunction with the Institute of Cancer Research and Cancer Research Technology. CHK1 is a serine/threonine kinase involved in regulating cell cycle checkpoint signals that are activated in response to DNA damage and DNA errors caused by defective replication. Activated CHK1 phosphorylates a number of downstream targets, which promote cell cycle arrest in S and G2/M phases of the cell cycle. There is now strong evidence that CHK1 inhibition may selectively sensitise p53 deficient cancer cells to genotoxic cancer therapies, through abrogation of the S and G2 checkpoints. Therefore CHK1 inhibitors may provide a therapeutic strategy for enhancing current genotoxic anticancer therapies. SAR-020106 has been shown to increase the activity of other anti-tumour agents in-vivo e.g. Irinotecan

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

The Company’s other cancer programmes; targeting Aurora+FLT3, Aurora+ALK and VEGFR3 kinases are being evaluated in in-vivo efficacy models. In February 2011, the Company announced significant progress against AML (acute myeloid leukaemia, the most common form of adult leukaemia) in its Aurora+FLT3 programme. A recent study for the programme showed that the leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated (ten in total) with a Sareum compound. By comparison, leukaemia increased five to fifteen fold in the study examples
treated without Sareum’s compound. At six weeks following treatment, no detectable cancer could be found in two of the ten examples dosed with the Sareum compound. In the remaining eight examples, the average time taken for the leukaemia to reappear and increase 5-fold was six weeks, compared
to two weeks in the untreated cases. This study compares very favourablywith similar studies published in the literature for the Aurora kinase inhibitors that are currently in clinical trials.

Funding
Sareum undertook share placings at 0.2p in August and December 2010 to raise £450,000, before expenses. In February 2011 a further £500,000 was raised at 1p a share. The funds raised will be used to progress the Aurora+FLT3 programme, and provide working capital for the foreseeable future.
Cash at bank at the end of December 2010 was £621,000, compared to £740,000 at the end of 2009. Losses on ordinary activities (after taxation) of £258,000 were £37,000 lower than in 2009.

Partnering approach
Sareum does not see itself as a pharmaceutical company and therefore has no intention to undertake a full programme of clinical studies to see a drug compound to market or put such a drug through a regulatory process. Sareum's strategy is to partner early stage programmes with large pharmaceutical companies. On their website they declare they are willing to do a licensing deal on the following basis:
  • Sponsored research whereby Sareum research costs are covered in exchange for programme ownership. The parties jointly out-license at a pre-agreed point
  • Research collaboration with a major partner on a jointly nominated target. The partner supports research costs of project and has first option to license the programme at a pre-agreed point
  • Straight license deal of a Sareum wholly owned programme at a pre-defined stage of development, e.g. Preclinical candidate nomination
SWOT
Strengths
Good molecular targets which have a key role in cancer tumour development
Management team has strong expertise in this area

Weaknesses
Relatively weakly funded - around £1 million cash
Products are early stage development so probability of success is very low (only 1 in 6 development compounds make it to market on average)
Limited clinical data on key development molecules

Opportunities
Large pharma companies are actively seeking development products for in-licensing
Cancer (oncology) market is large and growing

Threats
Financial institutions only funding UK biotech/development companies with strings attached e.g. large discounts on placings
Licensing deals may be on big pharma terms meaning potential of royalties on sales rather than large up front payments

Share outlook
Sareum’s share’s currently trade at 1.5p (52 week range 0.22p-2.48p), with a market capitalisation of £22 million (shares in issue
1,450,597,713). With around £1 million (£621,000 end of December plus £500,000 placing in February) of cash remaining means that it likely that institutions will tapped again for funds, probably in the second half of 2011, after the February fund raising at 1p. This means more dilution for private investors who cannot take place in a placing unlike a rights issue.

Though Sareum’s portfolio of developments looks to have potential, finding a development partner will not be easy as it sounds without early clinical evidence confirming the commercial opportunity for a licensee . It is encouraging that results from the Aurora+FLT3 programme seem to have shown benefit in Leukaemia but the trial size was still very small being a phase I study. I am surprised that the company has not beenmore aggressive in getting funding to undertake more significant early stage research, but this may be a reflection of sentiment towards small pharmaceutical developers after so many recent failures of UK biotechs.


Major pharmaceutical companies will seek to extract a hard bargain on any licensing deals with royalty based model on sales rather than large upfront payments to derisk their investment (why pay up front, when this means increasing the risk for the licensee company). This could mean that significant revenue from royalties may be a decade away given it takes 7-10 years to bring a new drug to market. Assuming of course it succeeds, and 84% of drugs fail!

Of course this share might well double just on the “froth” following announcements relating to its development pipeline but then again it might half if results are disappointing. This is the way with early stage drug development. With less than a £1 million in the bank, Sareum can’t afford many failures. I won't be buying Sareum for the Contrarian Investor UK portfolio but its been a good opportunity to review the company's prospects. Sareum - an acorn that may one day grow into an Oak tree, but could be a long time growing!

Coming soon to Contrarian investor uk

Just putting finishing touches to posts on Sareum (sar), Vialogy (viy). Hopefully ready.tonight all being well.

Sense of realism finally hits stock markets

After all the worrying developments from the Middle East, rising inflation concerns both here and in China, oil above $100 a barrel, a bloated U.S. Deficit, Eurozone debt worries and weakening consumer sentiment it was always a surprise that the FTSE was still above 6,000 and the S&P 500 hit a level double its March 2009 low last week. The Ftse 100 fell 64  points today to 6,019 with the big banks falling nearly 4% over worries about European debt. U.S. markets were closed due to President's day.

The Contrarian Investor UK portfolio got a battering with Bowleven dropping to 307p, a pound of its recent highs and Rockhopper finishing at 250p, a drop of close to 140p in the last 3 weeks. Xcite continues to drift lower as we await the CPR document to 344p, it was trading at 400p to buy less than 2 weeks ago on takeover rumours. Now the rumours are more of a 350p institutional placing. Its been a bad month, roll on March!

Markets move to safe haven assets

Today the markets responded continuing unrest in the Middle East with a move to safe havens such as the US dollar, gold and silver. Silver hit a 30 year high of $33 an ounce and brent crude oil hit $104, up $2. Risk aversion meant that AIM stocks are looking pretty sick today apart from silver and gold plays. A stronger dollar could mean that commodity prices will drop as they are sold in U.S. Dollars.

Rockhopper (RKH) dropped as much as 5% this morning with a seller clearly in the background and with as much as a month to wait until results from the 14/10-4 well are known. I put some today into my SIPP pension fund at 252p together with some more of copper stock, Weatherly International.

Rockhopper 14/10-4 well spuds

Rockhopper have issued an RNS confirming that the 14/10-4 well has spudded on 19th February. The well is 2.3km from the discovery at Sea Lion 14/10-2.  This is an anticipated 38 day drill, but inevitably results are released before this, lets assume mid March.

Sunday, February 20, 2011

2008/2009 financial crisis - U.S. Financial crisis enquiry commission report and conclusions

On January 27th, the U.S. Financial Crisis Enquiry Commission delivered its report. It was created to "examine the causes, domestic and global, of the current financial and economic crisis in the United States." The Commission was established as part of the Fraud Enforcement and Recovery Act (Public Law 111-21) passed by Congress and signed by President Obama in May 2009. This independent, 10-member panel was composed of private citizens with experience in areas such as housing, economics, finance, market regulation, banking and consumer protection. Six members of the Commission were appointed by the Democratic leadership of Congress and four by the Republican leadership. The Commission’s statutory instructions set out 22 specific topics for inquiry and called for the examination of the collapse of major financial institutions that failed or would have failed if not for exceptional assistance from the government.

The Commission's findings are available at:

Conclusions: http://c0182732.cdn1.cloudfiles.rackspacecloud.com/fcic_final_report_conclusions.pdf
Full report: http://c0182732.cdn1.cloudfiles.rackspacecloud.com/fcic_final_report_full.pdf

Pessimism virus infects Rockhopper - great for a Contrarian!

I have been thinking about my Rockhopper (RKH) investment quite a bit recently as the share price continues its rapid decent following the 14/10-3 well result. Following the euphoria of Rockhopper's Sea Lion discovery on May 6th, 2010 not much has gone right for the Falkland Island oil explorers. Desire Petroleum exemplified the issues with wild oscillations in its share price, which inevitably lost most private investors money, and culminating in the disastrous Rachel North 14/15-2 well which was announced as an oil discovery on December 3rd 2010 and then 3 days later, news came it was actually water.

Its easy to fall in love with a share and when it comes to the Falkland Island explorers I do not fall into this camp. I generally have a massive degree of scepticism. Though I was lucky enough to benefit from Rockhopper's Sea Lion discovery, I manage my investments in the Falkland Islands oil explorers on fundamentals not on luck.

So looking at Rockhopper you have to reexamine the facts to be sure that your investment is not just a speculative no hoper.

Rockhopper has:

  • 170 million barrels of oil confirmed reserves following a CPR at Sea Lion (14/10-2) which is commercial on a standalone basis
  • Current market capitalisation of £700 million underpinned by Sea Lion find
  • Around £200 million in cash for at at least 6 further wells in the North Falkland basin
  • Live oil shows found 8km from Sea Lion with 14/10-3 well (though non commercial on a stand alone basis). The well encountered good quality reservoir; hydrocarbons were present; and the sands were charged. (see FT.com note below)
  • Given the proximity of the next well 14/10-4 (2 km from Sea Lion) high probability of success
  • Full programme of 3D seismics due by second half 2011
At the end of last week Sam Moody was pitching the story to the City, particularly the prospects for the next well (14/10-4) which is due to spud next week. It seems things went well, probably because the facts speak for themselves. The froth has left the Falkland Island oil shares and excessive pessimism is the watch word for now. Rockhopper is still risky and a lot rides on the next well but the probability of success looks enticing and Moody is almost laying his reputation on the line with the comments he was using last week. Though I was not at the meeting, I have a good source and he was impressed with the story, lets hope the market is next week!

Note:
Correction: Rockhopper Sea Lion discovery
Published: February 14 2011 04:47 | Last updated: February 14 2011 04:47
http://www.ft.com/cms/s/0/545dbce6-37e6-11e0-b91a-00144feabdc0.html#ixzz1EXNa0TZT
Saturday’s FT incorrectly stated that Rockhopper’s Sea Lion discovery was uncommercial on a stand-alone basis. Instead Rockhopper’s announcement on Friday referred to a recently drilled exploration well, 14/10-3, which it considered to be uncommercial on a stand-alone basis, despite encountering live oil.

Rockhopper Exploration Edison report 14th February 2011

Summary of Edison report on Rockhopper (RKH) 14th February 2011:
Although a significant oil find would have been the optimal outcome from well 14/10-3, two out of three successful wells would be at the upper stretch of exploration odds. This aggressively located exploration well was testing the extent of the Sea Lion fan and located 8km from the Sea Lion discovery. We see some clear positives from the result: the well encountered good quality reservoir; hydrocarbons were present; and the sands were charged. Reservoir development looks encouraging in the northern lobe of the fan and potentially in the newly identified S2 feature. RKH will now focus on drilling a number of appraisal wells on the southern lobe of the Sea Lion feature. We do not believe this result has any impact on the P50 for Sea Lion. The work moves from exploration geology to development geology. The sharp fall in the share price presents an interesting opportunity ahead of the lower risk first appraisal well, located within the Sea Lion Discovery Area.

The long game: Significant work programme ahead
A second CPR could be coming in H211. The timing will allow for data from the current drilling campaign and the additional 3D seismic currently being shot to be incorporated. It leaves time for the work required to model the reservoir distribution across the multiple stacked fans in Sea Lion. The system has an aerial extent of over 50km2, with current seismic showing strong indications of good reservoir packages elsewhere in the fan, which appears to have been confirmed by this well. Rockhopper has indicated that up to six wells may be required to fully appraise the field, and discussions are progressing to agree a new contract consisting of a possible three firm wells and five option extensions.

Valuation: Covered by existing find, with exploration upside
The current EV is c $701m. Using an $8/boe value for a commercial discovery (the RPS Energy CPR uses $17/boe) would suggest the market is pricing in net reserves of 87mmbbls. RKH believes that Sea Lion is commercial as a standalone discovery. While there are some concerns about a waxy crude, associated gas could be used for power and heat for an FPSO and we do not believe this will prove to be a major issue. Borders & Southern has made similar indications around its acreage, suggesting that a 100mmbbl find would be commercial. As the RKH acreage is in significantly shallower water, drilling and operating costs are likely to be lower.

Note: Net cash = $374 million (estimated post November placing)

UK biotech and pharma heads into troubled waters

Early in 2010, Anglo Swedish group AstraZeneca (AZN) announced that it was closing its UK Research and Development centre in Loughborough by the end of 2011 with the loss of up to 1800 jobs.  In January, U.S. based Pfizer (PFE) announced the closure of the Sandwich research facility with the loss of 1300 jobs. The excuse has been the continued consolidation of research facilities and the loss of incentives to operate in the U.K. versus other developed markets.

It is true that a series of drug price cuts in the U.K. under the last Labour government under the PPRS (Pharmaceutical Profit Regulation Scheme) to try and offset the rising drugs bill, has given less incentive to spend millions of pounds on facilities such as Sandwich, and more incentive to use low cost operations in places like India or those with higher tax breaks such as the United States. As I wrote in a previous Contrarian Investor UK post, "Is the big pharma model broken for good?,  the major pharmaceutical companies are beset by rising drug development costs, yet with a less productive research system than ever and large numbers of big selling products going off patent (http://contrarianinvestoruk.blogspot.com/2011/01/is-big-pharma-drug-model-broken-for.html).

U.K. biotech is not fairing much better. Many of the hoped for stars of the industry have had major drug failures over the last few years highlighting the fact that as few as 16% of new drugs ever make it through clinical trials. Those companies with just one or two development products have significant risks. There are plenty of home grown examples to illustrate this point.

The most infamous is probably British Biotech, a company founded in 1986 and once close to membership of the FTSE 100. Peter McCullagh was ditched as Chief Executive in 1998 when a whistleblower, Andew Millar, alleged that investors were deceived with an over-optimistic view of its cancer drugs.

Its key product marimastat was touted as the "cure for cancer", but ultimately failed in clinical studies and Millar alleged that bad data was concealed. Co-founder, Brian Richards (now Sir Brian), went on to be Chairman of Alizyme, which would ultimately have it own problems.  In May 2006, British Biotech's shares peaked at just shy of £33 valuing it at £1.3 billion, when the company merged with Vernalis in 2003, it was worth around £50 million.

Alizyme (AZN) had several promising compounds in late stage development for obesity (cetilistat), ulcerative colitis (Colal-Pred) and irritable bowel syndrome (renzapride). It ultimately went into receivership at the end of 2009 when all its products failed late stage clinical trials. It was particularly unlucky for Alizyme given the drugs had passed through earlier stage clinical trials having reached their end points successfully and about 50% of drugs fail phase III testing. It was floated on AIM in 1996 and moved to the full list in 2000, before it folded in 2009.

Antisoma (ASM) once a promising company focused on anti-cancer drugs, has seen all of them fail human testing. A few years ago, Antisoma was trading close to 50p, now it is 3p! Antisoma's last hope, AS1413 in leukaemia recently had disappointing results after its lead product AS1404 for lung cancer (in partnership with Novartis) bombed in phase III trials. Its has £23 million of cash left but little else.

Ark Therapeutics (AKT) shares were once over 150p, now they are less than 5p, after the company had to withdraw its European filing for its brain cancer drug Cerepro (sitimagene ceradenovec) after a negative opinion from European regulators in December 2009 who requested additional clinical trial data.

Recently skin care specialist, Renovo (RNVO), lost nearly three-quarters of their value after the scar treatments developer admitted that its main treatment Juvista has failed to meet its goals in a phase III clinical trial in scar revision surgery. Unlike Antisoma, Renovo has £44 million in the bank and one product left in phase II trials, Prevascar, and results from this study are expected in the second half of 2011 for skin scarring reduction.

Not many examples of out and out successes come to mind from U.K. biotech, though we have major pharmaceutical players such as Glaxo Smithkline, Astra Zeneca and Shire pharmaceuticals. Compare this with the U.S., where they have Genentech (now part of Roche), Amgen, Genzyme (now part of Sanofi Aventis), Imclone (now owned by BMS), Medimmune (owned by Astra). Why the difference? - luck or judgement?

Saturday, February 19, 2011

Next Contrarian Investor UK stock review for end February?

So I've done the following AIM company reviews since the start of 2011:
  • Gulf Keystone Petreoleum (GKP) - http://contrarianinvestoruk.blogspot.com/2011/02/gulf-keystone-petroleum-interesting.html
  • Xcite Energy(XEL) -http://contrarianinvestoruk.blogspot.com/2011/01/xcite-energy-should-prove-highly.html
  • Range Resources (RRL) - http://contrarianinvestoruk.blogspot.com/2011/02/range-resources-look-to-have-good.html
  • Weatherly International (WTI) - http://contrarianinvestoruk.blogspot.com/2011/01/weatherly-international-namibian-copper.html
Only Xcite Energy and Weatherley International have made it into the portfolio so far, though Range looked interesting.

I'd like ideas for reviews on AIM stocks outside the commodity area, since the Contrarian Investor UK portfolio is way too skewed towards oil and gas. Please comment with any ideas.

U.S. regulators recommend steps to prevent another Market Flash Crash

On May 6th 2010 U.S. Flash Crash the Dow Jones industrial average lost nearly 1,000 points in 20 minutes starting at 2.40pm (GMT-5). It finished the day down only 3% after losing nearly 10% during the Flash Crash when the market lost over $850 billion dollars in minutes. The Flash Crash caught out the Contrarian Investor UK portfolio given I had some Dow Jones index CFD positions which closed fortunately on guaranteed stops, but I still lost several thousand pounds that day.

A committee set up by the U.S. regulator, the SEC (Securities and Exchange commision), has said that 90% of all trading is now done by high-frequency computer driven trading and a third of all trades are related to ETFs (exchange traded funds), which can add to the lack of liquidity in a market during periods of excessive market volatility. During the Flash crash, sellers overwhelmed the market with sell orders and there were not enough buyers to soak up the demand.

To prevent another May 6th debacle, the committee has recommended charging high frequency traders higher access fees during peak hours, a “limit up/limit down” system that would allow stocks experiencing rapid declines to continue trading within a narrow range of prices and a ban on “naked access” by requiring that all direct access order routing to the market to occur through a registered broker.

The Times: Four rules to follow if you want to plunge into oil and gas

From TheTimes:  http://www.thetimes.co.uk/tto/business/columnists/article2919361.ece


Four rules to follow if you want to plunge into oil and gas
Martin Waller: Tempus
February 19 2011 12:01AM


When last our vessel approached the wilder shores of the oil and gas exploration sector, I did warn that these were choppy waters. These are shares much loved by private investors but not for widows and orphans, mostly. There are an unbelievable 87 oil and gas companies quoted on the Alternative Investment Market alone.

The City gossip mill suggests that there are a number of others eyeing a stock market float, encouraged by the surge in the oil price to above $100 a barrel since the start of the year. These include such exotica as 3Legs Resources, owned by the wealthy Jeffcock family of the Isle of Man, hence the name. This extracts gas from shale in Poland, the first time this controversial technique has been used in Europe. The company has lined up Tim Eggar, a former energy minister, as a potential chairman.

There are, as I see it, four ways of approaching investment in oil and gas. One is to go for the blue chips, companies that have been around and have proven reserves. You will not make a fortune out of these, but you may not lose one, either.

The granddaddy of the sector is Premier Oil, in the North Sea from 1971 and now active in Vietnam and Indonesia, ramping up oil production from 44,000 barrels per day (bpd) in 2011 to 75,000 bpd next year.

One of Tempus picks for 2010 was Northern Petroleum, a tiddler with reserves in the North Sea off the Netherlands. The shares are now trading, I am pleased to say, at 134¼p, 23 per cent above the price when I tipped them.


The second is to follow people who have a strong track record. Sir Bill Gammell is the former Scottish rugby international who founded Cairn Energy in 1980. Cairn is locked in an uncomfortable dispute with the Indian authorities over the sale of its Rajasthan reserves to Vedanta Resources, which would bring in a windfall of up to $9.6 billion. There is no guarantee that the deal will go through, but some analysts see this as a two-way bet. If Cairn is required to hold on to the asset, it will still be worth more than when the sale was announced in August. Angus McPhail, the veteran oil-watcher now at Investec, says that it is in the interests of the Indian authorities to allow the deal through, given their need for indigenous diesel fuel to power coal and iron ore production. Phil Corbett, at Royal Bank of Scotland, agrees: “Does the Indian Government really want to put a black mark over investment in India?”. Sir Bill wants to spend much of the money from Vedanta on exploring off Greenland. This is unproven territory, but his loyal army of investors would happily back him.

Also bogged down in local political issues is Tullow Oil, which is trying to sell assets in Uganda and only this week abandoned a well in Mauritania. The Ugandan deal has been delayed by the election there but, on the assumption that Yoweri Museveni is re-elected as president, the parties should go back to the negotiating table, Mr McPhail says.

The third approach is to plump for a region that, for geopolitical reasons, looks promising. There are several Western explorers in Kurdish Iraq again involved in a political dispute, including Heritage Oil, which this week disappointed investors with the discovery of gas, rather than oil, there. Heritage remains one of the sector’s possible bid targets.

In the Falklands, the stock market high flier Rockhopper also disappointed with a drilling report this month, having raised £206 million to fund further exploration in November. The company insists there are reserves near by; expect more news shortly.


The third area exciting investors is off Vietnam and Thailand. David Farrell, at Evolution Securities, likes Soco International, which should be producing 35,000 bpd in the not too distant future from two wells there. Mr Corbett also singles out Soco, whose assets alone support the share price, with unproven exploration in the Democratic Republic of the Congo probably thrown in for free.


Soco is another bid candidate. “Historically, this is a company that has been looked at by potential predators,” Mr Farrell says. Last year Dana Petroleum was bought by the Korea National Oil Corporation for £1.9 billion, after a hostile takeover battle. KNOC still plans to spend £3 billion or more on acquisitions, while its Chinese equivalent is equally deal-hungry.

Mr Farrell’s colleague, Richard Griffith, likes Cove Energy. This is partnering with Anadarko Petroleum, one of the biggest oil independents in the world, in offshore Mozambique, and there are further opportunities further north off Kenya.

Dana’s founder Tom Cross believed the deal undervalued the company, and the rise in the oil price suggests he may have had a point. Mr Cross is back as chairman of Parkmead, an AIM-quoted penny share that typifies our fourth investment strategy in oil and gas stocks, the wildcat stock pick. Latching on to a company with little in the way of assets is an easy way to make money if you choose the right one, but it is a lottery, even if it is linked to someone with a track record such as Mr Cross. The shares have rocketed since he joined, and Parkmead still has much to prove.

Portfolio review of the week - 19th February 2011

Despite continued violence in Bahrain and an increase in Chinese interest rates to curb inflation, the FTSE 100  ended only marginally down at 6,083, a decline of 4 points giving a 20 point or 0.3% rise over the week.  The Dow Jones Industrial Average  rose 73 points, or 0.6%, to 12,391 its highest close for two and a half years.The Nasdaq rose 2, to 2,834, its highest close since October 31, 2007.

Violence is escalating in Bahrain between Sunni Muslim rulers and its Shiite majority population. Though ICE Brent for April was slightly lower at $102.52, after trading from $100.73 to $103.50. WTI U.S. crude finished at $86, down 0.2%.

Despite a strong oil price this week, the Contrarian Investor UK portfolio has suffered a second week of weakness. Its been a week of selling as I have de-leveraged on Xcite Energy (XEL) and sold my stake in Angel Mining.

Xcite Energy (XEL) - Xcite lost 29p or nearly 8% this week to finish at 353p as rumours continue to grow of a fund raising at around 350p to accompany the CPR (Competent Persons Report) which will move contingent resources to proven reserves and allow field development to begin. Though the CPR is expected to be positive, giving reserves of 225-250 million barrels of oil for the Bentley field, at least £200 million in shares is likely to be placed with institutions. With the price spiking to close to 400p last week on takeover rumours and with the likelihood of share price weakness, I took the opportunity to sell some of the holding to allow funds for acquisitions of other shares in the case of a market fall.

Bowleven (BLVN) - Bowleven dropped yet another 3.2% this week with news from the Sapele 1 side track several weeks away. At 318p, this appears bargain basement given the resources already discovered in Cameroon but sales by the BT Pension fund have helped move down the price. Frustrating given the upside potential in this share and it is now 9p below the last placing in October 2010.

Rockhopper (RKH) - Rockhopper dropped another 5% this week with the impact of the market disappointment from the 14/10-3 North Falklands basin well still being felt. The spudding of 14/10-4 which is much closer to the SeaLion discovery is due any day.  On fundamentals Rockhopper now looks very cheap. Its market capitalisation of £682 million, means that with £200 million in the bank deducted, Sea Lion's 170 million barrels are valued at just over $4 a barrel with no upside whatsoever. 14/10-3 is likely to add 40 million barrels to the discovery alone. Painful to be down on this one, but I believe patience will be rewarded and buyers will return with 7 wells yet to be drilled and a high COS (probability of success) on the new well.

Angel Mining (ANGM) - I lost patience with Angel Mining after we went into the 3rd week of February with no news from their Nalulaq gold mine. In my view no news is bad news, so I sold. Good long term prospects but things are very tight on cash flow and the last thing investors need is a cash call or increase in the SEDA (equity drawdown agreement).

Weatherly International (WTI) - Good to see copper miner Weatherly bounce on Friday to 12.4p (but still 5% down on the week) on news that Blackrock Smaller Companies has built a 7% share. This doesn't surprise since the constantly widening spread seemed to indicate the the market makers were playing some sort of game to accomodate some large block buys. Its good to see Blackrock involved to a greater extent a long with Gartmore as production ramps up in this really exciting Namibian copper company.  I am sure that we won't be seeing 12p for long with Copper at record highs and so much news to come from WTI in the coming months. I put a big slug into my SIPP pension plan earlier in the week because the risk/reward was excellent at less than 12p.

Thursday, February 17, 2011

Warren Buffett's tips for investment success

As an avid Buffett and Berkshire Hathaway follower, I try to remember his investment advice which has served him well. If readers are wondering why I took the decision to top up on Rockhopper (despite its relatively high risk profile) and sell some Xcite (despite my liking of the company and its excellent prospects), please see points 1 "stay liquid", point 2 "buy when everyone else is selling",  point 7 "defense beats offense" below. 

As another of my investment heroes Jim Cramer also says, "diversify, diversify, diversify". I am failing badly here, too many oil and gas stocks and too much in Xcite Energy. But I have known this for some time, and hence taking exit points when they arise on Xcite. Though I am in loss positions on both Rockhopper and Bowleven  (though made some profits on both in earlier sales in 2011), I won't be selling these at a loss. The fundamentals still justify an investment on a risk versus reward basis. Lets not forget that Buffett was buying preferred shares in Goldman Sachs in 2009 when everyone else on Wall Street wouldn't touch the sector and for his risk he got an 8% coupon! This is the contrarian style of investing that I favour....and sometimes its damned hard being a Contrarian when the momentum is the other way.

Extract from March 2010 post (http://contrarianinvestoruk.blogspot.com/2010/03/warrne-buffets-berkshire-hathaway-shows.html).

Buffet’s advice for investment success is :
Stay liquid. "We will never become dependent on the kindness of strangers," he wrote. "We will always arrange our affairs so that any requirements for cash we may conceivably have will be dwarfed by our own liquidity. Moreover, that liquidity will be constantly refreshed by a gusher of earnings from our many and diverse businesses."
Buy when everyone else is selling. "We've put a lot of money to work during the chaos of the last two years. It's been an ideal period for investors: A climate of fear is their best friend ... Big opportunities come infrequently. When it's raining gold, reach for a bucket, not a thimble."
Don't buy when everyone else is buying. "Those who invest only when commentators are upbeat end up paying a heavy price for meaningless reassurance," Mr. Buffett wrote. The obvious corollary is to be patient. You can only buy when everyone else is selling if you have held your fire when everyone was buying.
Value, value, value. "In the end, what counts in investing is what you pay for a business-through the purchase of a small piece of it in the stock market-and what that business earns in the succeeding decade or two."
Don't get suckered by big growth stories. Mr. Buffett reminded investors that he and Berkshire Vice Chairman Charlie Munger "avoid businesses whose futures we can't evaluate, no matter how exciting their products may be.". Most investors who bet on the auto industry in 1910, planes in 1930 or TV makers in 1950 ended up losing their shirts, even though the products really did change the world. "Dramatic growth" doesn't always lead to high profit margins and returns on capital. China, anyone?
Understand what you own. "Investors who buy and sell based upon media or analyst commentary are not for us," Mr. Buffett wrote.
Defense beats offense. "Though we have lagged the S&P in some years that were positive for the market, we have consistently done better than the S&P in the eleven years during which it delivered negative results. In other words, our defense has been better than our offense, and that's likely to continue." All timely advice from Mr. Buffett for turbulent times.
(original source: marketwatch.com)

Derisked holding in Xcite Energy

The word in the City is that the Xcite's CPR is due any day and its positive. No need to re do the flow test that's for certain. The directors aren't so stupid to sign for the Rowan Norway rig with that sort of scenario.
But the rumours of a placing to accompany this news is building. Somewhere in 350p region seems to be consensus, but i hear talk of less. I sold a little more on the spike up this morning, to diversify the portfolio more. Still love the Xcite story but no point taking a big hit. The institutions aren't handing out cash like they were and want a big discount. The number of commodity flotations pulled in the last 2 weeks underscores the weakness in the market for new listings and placings. I am hoping that the Bentley Alliance route is used rather than institional money but details are vague here. I'm taking a cautious approach and this may be nothing more than a "storm in a teacup".